Hanmi Pharm Co Ltd
KRX:128940
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
245 000
366 169.2238
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hanmi Pharm Co Ltd
Hanmi Pharm Co Ltd
Selling, General & Administrative
Hanmi Pharm Co Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Selling, General & Administrative
-₩425.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-6%
|
|
|
Yuhan Corp
KRX:000100
|
Selling, General & Administrative
-₩394.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-7%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Selling, General & Administrative
-₩208.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Selling, General & Administrative
-₩190B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-14%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Selling, General & Administrative
-₩83.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-7%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Selling, General & Administrative
-₩66.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Hanmi Pharm Co Ltd
Glance View
Hanmi Pharm Co., Ltd. is a remarkable player in the pharmaceutical industry hailing from South Korea, a country renowned for its technological and medical advancements. The company's journey began in 1973, and it has since carved out a substantial niche within the pharma sector by focusing on innovative research and development. Hanmi Pharm has been particularly recognized for its strong pipeline in pharmaceuticals addressing diabetes, oncology, and autoimmune diseases. It leverages its cutting-edge proprietary technology platforms such as LAPSCOVERY, which is dedicated to creating long-acting biologics, and Quantum Project, focused on novel small molecule drugs. These platforms are pivotal to Hanmi's strategy, enabling it not only to excel in creating new drugs but also to foster partnerships and licensing deals on a global scale, which constitute a significant revenue stream for the company. Beyond innovation, Hanmi Pharm has diversified its business operations across various sectors of pharmaceuticals including finished goods, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company's revenue model is multifaceted and robust; it generates income by selling its pharmaceuticals in domestic and international markets and taps into significant contract manufacturing opportunities. Additionally, Hanmi Pharm has managed to establish strategic alliances with global pharmaceutical giants, resulting in lucrative licensing agreements. These collaborations allow Hanmi to not only broaden its distribution channels but also enhance its R&D capabilities by synergizing with the technological prowess of its partners. Through these multifarious routes, Hanmi Pharm has built a complex, enduring, and well-oiled machine that propels its financial growth and sustains its competitive edge within the industry.
See Also
What is Hanmi Pharm Co Ltd's Selling, General & Administrative?
Selling, General & Administrative
-425.8B
KRW
Based on the financial report for Sep 30, 2024, Hanmi Pharm Co Ltd's Selling, General & Administrative amounts to -425.8B KRW.
What is Hanmi Pharm Co Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-6%
Over the last year, the Selling, General & Administrative growth was -3%. The average annual Selling, General & Administrative growth rates for Hanmi Pharm Co Ltd have been -7% over the past three years , -6% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet
